Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 8;40(8):1409–1424. doi: 10.1038/s41388-020-01621-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021, corrected publication 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a, b HEC-1B and ARK-2 cells were incubated with PFK158, CBPt/Cis at a range of concentrations, both individually and in combination for 72 h, and cell viability was measured by clonogenic assays. The synergistic inhibitory effect of PFK158 and CBPt/Cis combination is shown in HEC-1B and ARK-2 cells. All experiments were performed in triplicate. Representative images of plates are shown. c, d Normalized isobologram (obtained with Calcusyn software) over a range of PFK158 and CBPt or Cis dosage combinations. The combination index (CI) was plotted as a function of dose combination, with average CIs for the drug combination reported in the panel. The additive isobole is depicted in this panel as a red straight line, with synergistic dose combinations labeled below the isobole. An average CI of 1 indicates an additive effect, CI < 1 a synergistic effect, and CI > 1 an antagonistic effect.